NBC Securities Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 102,995.0% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 41,238 shares of the company's stock after purchasing an additional 41,198 shares during the period. Johnson & Johnson makes up approximately 0.6% of NBC Securities Inc.'s investment portfolio, making the stock its 20th largest position. NBC Securities Inc.'s holdings in Johnson & Johnson were worth $6,838,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in JNJ. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $29,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $32,000. Conquis Financial LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $33,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $36,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts recently commented on the stock. Bank of America dropped their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Barclays lowered their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.
Check Out Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Price Performance
JNJ traded up $0.47 during midday trading on Thursday, reaching $153.69. 1,726,134 shares of the company's stock were exchanged, compared to its average volume of 7,915,623. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $369.79 billion, a PE ratio of 23.11, a P/E/G ratio of 2.56 and a beta of 0.42. The business's 50-day moving average price is $153.81 and its 200 day moving average price is $153.67. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson's payout ratio is 57.84%.
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
